Bruker (NASDAQ:BRKR) Shares Down 7.1% – What’s Next?

Bruker Corporation (NASDAQ:BRKR)’s stock price traded down 7.1% during trading on Wednesday . The company traded as low as $55.08 and last traded at $54.21. 230,821 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 2,339,288 shares. The stock had previously closed at $58.37.

Analyst Ratings Changes

Several equities analysts have issued reports on BRKR shares. Wolfe Research started coverage on Bruker in a research report on Monday, June 1st. They set a “peer perform” rating on the stock. Zacks Research cut Bruker from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 2nd. JPMorgan Chase & Co. lifted their price target on Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. UBS Group assumed coverage on Bruker in a report on Wednesday. They set a “neutral” rating and a $65.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a research report on Monday, August 31st. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $57.00.

Bruker Stock Performance

The stock’s 50-day moving average price is $58.41 and its 200-day moving average price is $49.22. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85. The company has a market capitalization of $8.16 billion, a price-to-earnings ratio of -76.51, a P/E/G ratio of 1.66 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The business had revenue of $838.50 million for the quarter, compared to analysts’ expectations of $853.57 million. During the same quarter in the prior year, the firm posted $0.32 EPS. The company’s revenue was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities research analysts expect that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, September 21st. Bruker’s payout ratio is presently -28.57%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BRKR. Hsbc Holdings PLC acquired a new stake in shares of Bruker in the second quarter valued at approximately $5,252,000. Thrivent Financial for Lutherans raised its position in shares of Bruker by 561.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 179,792 shares of the medical research company’s stock worth $8,470,000 after purchasing an additional 152,603 shares during the last quarter. Edmond DE Rothschild Holding S.A. acquired a new position in shares of Bruker during the 2nd quarter worth approximately $169,899,000. Hantz Financial Services Inc. lifted its stake in Bruker by 202.7% in the 4th quarter. Hantz Financial Services Inc. now owns 41,306 shares of the medical research company’s stock valued at $1,946,000 after buying an additional 27,659 shares in the last quarter. Finally, Fifth Third Bancorp lifted its stake in Bruker by 4,058.3% in the 1st quarter. Fifth Third Bancorp now owns 57,135 shares of the medical research company’s stock valued at $2,064,000 after buying an additional 55,761 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.